T cell cytotoxicity to Epstein-Barr virus infected B cells: comparison of patients with rheumatoid arthritis and their HLA identical siblings

VIVIENNE R WINROW,1 JANICE NORTON,1 E JOHN HOLBOROW,1 HELMUT E STIERLE,1* ADAM YOUNG,2 AND JOHN A SACHS1

From the 1ARC Bone and Joint Research Unit, The London Hospital Medical College, London; and 2St Albans City Hospital, Herts, England

SUMMARY  Specific T cell cytotoxicity to Epstein-Barr virus (EBV) infected B cells is reported to be abnormal in rheumatoid arthritis (RA). The regression phenomenon was used to determine whether the immunoregulatory defect in RA is restricted to T cells, B cells, or HLA type. Peripheral blood T and B cells from patients with RA and their HLA identical healthy siblings were mixed in varying ratios with and without EBV, and thymidine incorporation was measured on days 7, 14, and 21. The results suggest that the T cell abnormality is related to disease activity and that an inherent defect exists in the rheumatoid B cell which is independent of disease activity.

Key words: T lymphocyte, immune regulation.

The underlying deficiency of immunoregulation in rheumatoid arthritis (RA) is unknown, though disturbances in humoral and cellular immunity are well documented. The Epstein-Barr virus (EBV), originally implicated in the pathogenesis of RA,1,2 has since been used to study the cellular immunity defect in RA through its ability to transform B lymphocytes into lymphoblastoid cell lines in vitro. Healthy individuals previously infected with EBV possess specific memory T cells which can abrogate B cell outgrowth in mononuclear cell cultures after superinfection with the virus ("regression"3), whereas rheumatoid T cells appear to show impairment of this ability.4-7 An alternative explanation is that it is not poor T cell regulation but an inherent defect in rheumatoid B cells which renders them unresponsive to regulation.8-10 In this study specific T cell cytotoxicity to EBV infected B cells was measured using blood lymphocytes from patients and their HLA identical siblings to ascertain whether the immunoregulatory defect in RA is governed by B cell or T cell behaviour.

Patients and methods

Patients
Families of patients at St Alban's Hospital were recruited and disease activity assessed clinically (AY). Each family consisted of a patient with classical RA and at least two apparently healthy siblings. Tissue typing was performed in the immunology department of the London Hospital Medical College by standard procedures.

Cell separation
On the day of collection venous peripheral blood mononuclear cells were isolated by flotation11 on Lymphoprep (Nyegaard), washed in serum free medium, and resuspended in RPMI 1640 with L-glutamine to which had been added 10% fetal calf serum and 100 units/ml of penicillin/streptomycin (culture medium; Gibco Biocult). The cells were mixed with 2-aminoethyliodothiouronium bromide hydrobromide treated sheep erythrocytes,12 pelleted, maintained at 4°C for 60 minutes, and gently resuspended. The suspension was layered on Lymphoprep and the rosetted T cells separated from the non-T cells. Erythrocytes were removed from the enriched T cell population in the pellet by lysis with 0-83% ammonium chloride, and the cells were washed in serum free medium and resuspended to a...
T cell cytotoxicity to Epstein-Barr virus infected B cells

final concentration of $5 \times 10^7$ ml in culture medium. Non-T cells recovered from the interface were washed and resuspended at a concentration of $5 \times 10^7$ ml in culture medium or were incubated with EBV in culture medium for one hour at 37°C before washing and resuspending at $5 \times 10^7$ ml in culture medium.

**EBV Preparation**

Epstein-Barr virus, used for B cell transformation, was obtained from 10 day culture supernatants of the marmoset cell line B95-8 and titrated against fetal cord blood cells. The virus preparation used for all experiments was stored in aliquots in liquid nitrogen, each aliquot being thawed once immediately before use and used at a final dilution of 1 in 10.

**Outgrowth Assay**

Unfractionated mononuclear cells and T and non-T cells ($5 \times 10^7$ ml) were incubated separately in 24-well, flat bottomed plates (Nunc) with and without EBV for six weeks. Duplicate or triplicate cultures (1 ml) were set up, depending on cell numbers, and the medium was replaced weekly. B cell outgrowth was scored visually every two or three days using the method of Thorley-Lawson, Chess, and Strominger to check for induced or spontaneous outgrowth of cell lines and bacterial contamination.

**Regression Assay**

T and non-T cells were added to 96-well, flat bottomed microtitre plates (Nunc) to give a final cell number of $1 \times 10^7$ in 200 ml culture medium. T/non-T cell ratios of 100/0, 90/10, 75/25, 50/50, 25/75, 10/90, and 0/100 were used. EBV infected non-T cells from each sibling were mixed with either autologous T cells or allogeneic T cells from an HLA identical sibling. The cultures were set up in triplicate on each of three plates and a fourth control well contained cell mixtures without EBV to check for mixed lymphocyte reactions; non-T cell numbers were too small to set up triplicate samples of control wells. The plates were incubated at 37°C in a humidified atmosphere of 5% CO₂ for up to three weeks and the culture medium replaced on days 6, 13, and 20. Each week, immediately after feeding, 37 kBq of $[^\text{3}H]$thymidine was added to each well of one plate, and 18 hours later the cells were harvested on glass microfibre discs (Whatman GF/A), dried, and counted (Kontron MR300) using a toluene based scintillant. Before harvesting, cell cultures were scored for B cell outgrowth as above.

**Results**

In only three of eight families tissue typed were siblings found of the same HLA identity as the patient (Table 1). The results for families 1 and 2 will be discussed in detail here. In both families the patients were DR4 positive and had longstanding seropositive RA. The patient in family 1 had clinically active disease according to American Rheumatism Association criteria at the time of

<table>
<thead>
<tr>
<th>Patient</th>
<th>T cells (%)</th>
<th>Patient T cells</th>
<th>Healthy T cells (sibling A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
<td>(cpm)*</td>
<td>T-L score</td>
<td>+EBV (cpm)*</td>
</tr>
</tbody>
</table>

*The mean cpm of triplicate samples is shown.

**Table 2 Correlation of outgrowth with proliferation of EBV infected rheumatoid B cells cultured with autologous and homologous T cells (family 1, day 14)**

<table>
<thead>
<tr>
<th>Patient</th>
<th>T cells (%)</th>
<th>Patient T cells</th>
<th>Healthy T cells (sibling A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B cells</td>
<td>(%)</td>
<td>+EBV (cpm)*</td>
<td>T-L score</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>100</td>
<td>0</td>
<td>11 105</td>
<td>4</td>
</tr>
<tr>
<td>90</td>
<td>10</td>
<td>16 824</td>
<td>4</td>
</tr>
<tr>
<td>75</td>
<td>25</td>
<td>16 826</td>
<td>4</td>
</tr>
<tr>
<td>50</td>
<td>50</td>
<td>18 196</td>
<td>4</td>
</tr>
<tr>
<td>25</td>
<td>75</td>
<td>18 196</td>
<td>4</td>
</tr>
<tr>
<td>10</td>
<td>90</td>
<td>8 948</td>
<td>4/1</td>
</tr>
<tr>
<td>0</td>
<td>100</td>
<td>1 113</td>
<td>2/1</td>
</tr>
</tbody>
</table>

**Seropositive: 11 years RA with intermittent active disease. Indomethacin/D-penicillamine/low dose steroid**

**Seropositive: ‘burnt out’: 15 years RA with inactive disease for four years. Paracetamol**

**Seropositive with active disease**

Table 1 Tissue types of disease discordant siblings and clinical details and treatment of rheumatoid patients

<table>
<thead>
<tr>
<th>Family (total number of siblings)</th>
<th>Disease discordant siblings</th>
<th>HLA type</th>
<th>Age/sex</th>
<th>Clinical notes and treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (6)</td>
<td>RA patient</td>
<td>A2,3: B7,w62: DR2,4</td>
<td>46/M</td>
<td>Seropositive: 11 years RA with intermittent active disease. Indomethacin/D-penicillamine/low dose steroid</td>
</tr>
<tr>
<td></td>
<td>Sibling A</td>
<td>52/M</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sibling B</td>
<td>40/F</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 (3)</td>
<td>RA patient</td>
<td>A31,32: B44,51: DR4,7</td>
<td>72/F</td>
<td>Seropositive: ‘burnt out’: 15 years RA with inactive disease for four years. Paracetamol</td>
</tr>
<tr>
<td></td>
<td>Sibling A</td>
<td>68/F</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sibling B</td>
<td>75/F</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 (4)</td>
<td>RA patient</td>
<td>A2,11: B44,49: Cw5,w7</td>
<td>/F</td>
<td>Seropositive with active disease</td>
</tr>
<tr>
<td></td>
<td>Sibling A</td>
<td>/F</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Thorley-Lawson score (2 = two wells).*
In the outgrowth assay (24-well plates; no thymidine), all cultures of unfractionated cells regressed. T cell enriched populations from either rheumatoid or healthy siblings did not form cell lines, though B cell outgrowth persisted for up to 20 days in cultures of isolated non-T cells from both patients but not their HLA identical healthy siblings. Thorley-Lawson and coworkers described a scoring system of 1-4, judged by phase contrast microscopy, where 1 represented dead cells; 2 living but not necessarily transformed cells; 3 transformed cell clumps; 4 a culture well overrun by transformed and proliferating cells. In the regression assay, whereas in the patient in family 2 disease had been inactive for the last four years before testing, T cell cultures from healthy siblings, isolated non-T cells, and an erythrocyte sedimentation rate of less than 25 mm/h. Table 1 also shows the treatments for these two patients.

Fig. 1. Specific T cell cytotoxicity to EBV infected B cells in family 1. Non-T cells from each sibling (a) patient; (b) sibling A; (c) sibling B were transformed with EBV, and autologous or allogeneic T cells were added at different ratios. T cells are coded -- (patients with RA), * (sibling A); -- (sibling B).
Regressing cultures scoring 1 (dead cells) or 3/1 (small clusters of regressing transformed cells amongst dead cells) showed, respectively, background or slightly raised thymidine uptake. Table 2 gives an example referring to Fig. 1a.

Fig. 1 shows the regression assay results obtained with family 1 on day 14 of culture. B cells from the patient with RA were used in Fig. 1a: more than 75% autologous rheumatoid T cells (T/B ratio of 3/1) were required to prevent B cell outgrowth in contrast with 50% (T/B ratio of 1/1) HLA identical allogeneic normal T cells. This affirms that T cells from the rheumatoid patient show a defective cytotoxic response. This patient’s T cells were also less able to control the homologous B cell outgrowth from the HLA identical siblings (Figs 1b and c).

Fig. 2 shows the results obtained with family 2 on day 14 of culture. In this family the disease in the patient had been inactive for four years. There was no significant difference in thymidine uptake between the cells of the rheumatoid patient and the unaffected siblings at 14 days.

For both families there were no differences in thymidine uptake at seven days. At 21 days thymidine incorporation showed baseline values in family 1 but in family 2 some thymidine incorporation was
seen at high rheumatoid T cell numbers (75%), irrespective of whether the B cells were rheumatoid or normal in origin (data not shown).

Results obtained with family 3 (Table 1) require comment. This patient with RA also had clinically active disease at the time of venepuncture. The cells, however, became contaminated during the manipulations and subsequent culture and, at 14 days, only the plate containing rheumatoid B cells with autologous or healthy allogeneic HLA identical T cells remained uncontaminated. The results were comparable with those in Fig. 1a, the deficiency in T cell control being apparent at B:T cell ratios of 25:75 (data not shown). At seven days thymidine uptake was similar in both autologous and homologous cultures.

**Discussion**

Families provide a means of obtaining HLA identical, disease discordant individuals, for whom any differences in the behaviour of their cells can be ascribed to disease rather than HLA type. This study contrasts three families each containing a patient with rheumatoid arthritis and healthy HLA identical siblings, the patients having either active (families 1 and 3) or inactive (family 2) rheumatoid disease.

It has been shown that regression is attributable to both EBV specific T cell cytotoxicity and non-specific autologous mixed lymphocyte reactions and that much of the thymidine uptake by in vitro EBV infected cells at seven days is due to the concomitant T cell expansion. In a previous study we concluded that enhanced thymidine incorporation at seven days by unfractionated cells from rheumatoid patients was indicative of B cell hyperresponsiveness. We now have further evidence, however, showing that other cell populations are responsible for the increased thymidine uptake and also that viral dose is an important factor in measurement of this hyperresponsiveness. In this study there was no significant difference in thymidine uptake at seven days between any of the cultures (results not shown). As regression normally occurs 10–14 days after in vitro stimulation, any actively dividing cells present on day 14 in cultures not having completely regressed should be virus infected B cells, and it was at this time that differences in thymidine uptake were noted. Table 2 shows that the amount of thymidine incorporation appeared to represent the degree of regression, though no absolute correlations were made.

The patient in family 1 with active disease at the time of assay presents a picture (Fig. 1a) typical of results obtained by others using non-HLA matched individuals, and the patient in family 3 also showed this pattern of reactivity. In family 2, where the patient had ‘burnt out’ RA, the picture (Fig. 2a) is quite different, being indicative of normal T cell cytotoxicity. Isolated B cells from both rheumatoid patients, however, formed permanent cell lines in the absence of EBV. This was not true of their histocompatible siblings, confirming our previous conclusion that rheumatoid B cells are abnormal in this respect.

The outgrowth measured at 21 days in family 2 requires comment. Increased thymidine levels were noted (20 000–40 000 cpm). This may reflect a lack of control by rheumatoid T cells but is more likely due to rheumatoid B cell contamination of the rheumatoid T cell population as the EBV infected rheumatoid T cell population also showed some outgrowth of B cells, which regressed at 20 days. It must be remembered that the cell populations are merely enriched for the various cell types and do not represent pure B and T cells.

One interesting aspect of these results is the age difference of these families. Within each family age matching is reasonably close, but the age differences between families 1 and 2 are considerable, the patient in family 2 being almost 30 years older than the patient in family 1. Most studies measuring age related differences of immunity imply that T cell cytotoxicity is impaired in older individuals. Here, the T cells of the older patient (family 2) behaved efficiently, but the T cells of the younger patient (family 1) were defective. This is consistent with our argument that the poor T cell regulation of the patient in family 1 is disease related. Others have suggested that the ‘strength’ of regression is related to the degree of matching of major histocompatibility complex class 1 antigens, which is clearly not the explanation of the results in these experiments. It is possible that there are sex related differences, but this study was not designed to assess that problem. Sibling B (F) in family 1 showed some impairment in T cell control of EBV infected B cells (Fig. 1b) from sibling A (M). All three siblings in family 2 were female.

Because of the small number of families recruited the information available from this study is limited; it suggests, however, that the inability of rheumatoid T cells to regulate B cell outgrowth is related to disease activity, and studies by Gaston and co-workers lend support to this conclusion. Also, it appears that the defect in T cell control in RA is reversible as the T cells of the patient with burnt out RA and those of the HLA identical siblings were equally effective in the regression assay. Recent work, also using disease discordant histocompatible siblings, has shown abnormalities in
the suppression of IgM production by EBV infected rheumatoid B cells, but no correlations were looked for with disease activity. In our study antibody production was not measured. Nevertheless, the spontaneous production of B cell lines by isolated non-T cells from the patients in families 1 and 2 supports our previous data from limiting dilution analysis, 10 suggesting that there is an inherent B cell defect in RA which is disease related but, unlike the rheumatoid T cell defect, independent of disease activity.

We thank Daniel McCloskey and Juliette Awad of the department of immunology (Professor H Festenstein) for tissue typing the families. VRW was supported by the Arthritis and Rheumatism Council for Research.

References
T cell cytotoxicity to Epstein-Barr virus infected B cells: comparison of patients with rheumatoid arthritis and their HLA identical siblings.

V R Winrow, J Norton, E J Holborow, H E Stierle, A Young and J A Sachs

doi: 10.1136/ard.47.4.280